Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


Articles published in J Neurochem

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    November 2021
  1. GUO YJ, Ayton S, Lei P
    Iron reduces the propagation of pathological alpha-synuclein: An Editorial Highlight for "Brain iron enrichment attenuates alpha-synuclein spreading after injection of preformed fibrils" on page 554.
    J Neurochem. 2021;159:414-416.
    PubMed     Abstract available


    October 2021
  2. LEE CY, Menozzi E, Chau KY, Schapira AHV, et al
    Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes.
    J Neurochem. 2021 Oct 7. doi: 10.1111/jnc.15524.
    PubMed     Abstract available


    September 2021
  3. BIDESI N, Andersen IV, Windhorst AD, Shalgunov V, et al
    The Role of Neuroimaging in Parkinson's Disease.
    J Neurochem. 2021 Sep 17. doi: 10.1111/jnc.15516.
    PubMed     Abstract available


    July 2021
  4. GOLDSTEIN DS, Sullivan P, Holmes C, Lamotte G, et al
    Differential abnormalities of cerebrospinal fluid dopaminergic versus noradrenergic indices in synucleinopathies.
    J Neurochem. 2021;158:554-568.
    PubMed     Abstract available


    June 2021
  5. MASATO A, Bubacco L, Greggio E
    Too much for your own good: Excessive dopamine damages neurons and contributes to Parkinson's disease: An Editorial Highlight for "Enhanced tyrosine hydroxylase activity induces oxidative stress, causes accumulation of autotoxic catecholamine metaboli
    J Neurochem. 2021 Jun 28. doi: 10.1111/jnc.15442.
    PubMed     Abstract available


  6. KHAIRNAR A, Ruda-Kucerova J, Arab A, Hadjistyllis C, et al
    Diffusion kurtosis imaging detects the time-dependent progress of pathological changes in the oral rotenone mouse model of Parkinson's disease.
    J Neurochem. 2021 Jun 9. doi: 10.1111/jnc.15449.
    PubMed     Abstract available


    May 2021
  7. LASHUEL HA
    Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monit
    J Neurochem. 2021;157:891-898.
    PubMed     Abstract available


    April 2021
  8. PISCHEDDA F, Piccoli G
    LRRK2 at the pre-synaptic site: A 16-years perspective.
    J Neurochem. 2021;157:297-311.
    PubMed     Abstract available


    January 2021
  9. LV Q, Zhong Z, Hu B, Yan S, et al
    MicroRNA-3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson's disease.
    J Neurochem. 2021 Jan 15. doi: 10.1111/jnc.15299.
    PubMed     Abstract available


    December 2020
  10. PINNELL JR, Cui M, Tieu K
    Exosomes in Parkinson Disease.
    J Neurochem. 2020 Dec 29. doi: 10.1111/jnc.15288.
    PubMed     Abstract available


  11. ZARATE SM, Pandey G, Chilukuri S, Garcia JA, et al
    Cytisine is neuroprotective in female but not male 6-hydroxydopamine lesioned parkinsonian mice and acts in combination with 17-beta-estradiol to inhibit apoptotic endoplasmic reticulum stress in dopaminergic neurons.
    J Neurochem. 2020 Dec 23. doi: 10.1111/jnc.15282.
    PubMed     Abstract available


  12. HADI F, Akrami H, Totonchi M, Farhadi A, et al
    alpha-Synuclein Abnormalities Trigger Focal Tau Pathology, Spreading to Various Brain Areas in Parkinson's Disease.
    J Neurochem. 2020 Dec 2. doi: 10.1111/jnc.15257.
    PubMed     Abstract available


    September 2020
  13. TUO QZ, Lei P
    Iron promotes the clearance of alpha-synuclein: An Editorial for 'H63D variant of the homeostatic iron regulator (HFE) gene alters alpha-synuclein expression, aggregation, and toxicity" on page 177.
    J Neurochem. 2020;155:117-119.
    PubMed     Abstract available


    August 2020
  14. TRINH D, Israwi AR, Arathoon LR, Gleave JA, et al
    The multi-faceted role of mitochondria in the pathology of Parkinson's disease.
    J Neurochem. 2020 Aug 16. doi: 10.1111/jnc.15154.
    PubMed     Abstract available


    July 2020
  15. TOFFOLI M, Smith L, Schapira AHV
    The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers.
    J Neurochem. 2020;154:11-24.
    PubMed     Abstract available


    April 2020
  16. NICHOLS MR
    Disentangling aggregation-prone proteins: a new method for isolating alpha-synuclein species: An Editorial Highlight for "A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of alpha-synuclein m
    J Neurochem. 2020;153:7-9.
    PubMed     Abstract available


  17. KUMAR ST, Donzelli S, Chiki A, Syed MMK, et al
    A simple, versatile and robust centrifugation-based filtration protocol for the isolation and quantification of alpha-synuclein monomers, oligomers and fibrils: Towards improving experimental reproducibility in alpha-synuclein research.
    J Neurochem. 2020;153:103-119.
    PubMed     Abstract available


    March 2020
  18. KATAURA T, Shinji S, Ishikawa KI, Akamatsu W, et al
    BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model.
    J Neurochem. 2020 Mar 3. doi: 10.1111/jnc.14997.
    PubMed     Abstract available


  19. HORTNAGL H, Pifl C, Hortnagl E, Reiner A, et al
    Distinct gradients of various neurotransmitter markers in caudate nucleus and putamen of the human brain.
    J Neurochem. 2020;152:650-662.
    PubMed     Abstract available


    January 2020
  20. SANPHUI P, Das AK, Biswas SC
    FoxO3a requires BAF57, a subunit of chromatin remodeler SWI/SNF complex for induction of PUMA in a model of Parkinson's disease.
    J Neurochem. 2020 Jan 23:e14969. doi: 10.1111/jnc.14969.
    PubMed     Abstract available


    November 2019
  21. COGO S, Manzoni C, Lewis PA, Greggio E, et al
    Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.
    J Neurochem. 2019 Nov 6. doi: 10.1111/jnc.14908.
    PubMed     Abstract available


    October 2019
  22. CORREIA GUEDES L, Mestre T, Outeiro TF, Ferreira JJ, et al
    Are genetic and idiopathic forms of Parkinson's disease the same disease?
    J Neurochem. 2019 Oct 23. doi: 10.1111/jnc.14902.
    PubMed     Abstract available


    September 2019
  23. OUTEIRO TF, Mestre TA
    Synuclein Meeting 2019: where we are and where we need to go.
    J Neurochem. 2019;150:462-466.
    PubMed     Abstract available


  24. WASSOUF Z, Schulze-Hentrich JM
    Alpha-synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease.
    J Neurochem. 2019;150:591-604.
    PubMed     Abstract available


  25. KILLINGER BA, Kordower JH
    Spreading of alpha-synuclein - relevant or epiphenomenon?
    J Neurochem. 2019;150:605-611.
    PubMed     Abstract available


  26. GONZALEZ N, Arcos-Lopez T, Konig A, Quintanar L, et al
    Effects of alpha-synuclein post-translational modifications on metal binding.
    J Neurochem. 2019;150:507-521.
    PubMed     Abstract available


  27. STEFANIS L, Emmanouilidou E, Pantazopoulou M, Kirik D, et al
    How is alpha-synuclein cleared from the cell?
    J Neurochem. 2019;150:577-590.
    PubMed     Abstract available


  28. VAIKATH NN, Hmila I, Gupta V, Erskine D, et al
    Antibodies against alpha-synuclein: tools and therapies.
    J Neurochem. 2019;150:612-625.
    PubMed     Abstract available


    August 2019
  29. BOONYING W, Joselin A, Huang E, Qu D, et al
    Pink1 regulates FKBP5 interaction with AKT/PHLPP and protects neurons from neurotoxin stress induced by MPP(.)
    J Neurochem. 2019;150:312-329.
    PubMed     Abstract available


    April 2019
  30. MOLLENHAUER B, Bowman FD, Drake D, Duong J, et al
    Antibody-based methods for the measurement of alpha-synuclein concentration in human cerebrospinal fluid - method comparison and round robin study.
    J Neurochem. 2019;149:126-138.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: